Primary Cardiac Lymphoma

Cancer of the heart is rare enough that the National Cancer Institute (NCI) does not specifically track its incidence. When cancer develops in the heart, it is considered a soft tissue sarcoma (a sarcoma is any cancer that develops in soft tissue). The NCI estimates that about 11,000 people will be diagnosed with a soft tissue sarcoma in the US every year (1). By way of comparison, that is about the same number of new cases of both Hodgkin's lymphoma and testicular cancer.

When the heart is the primary site of cancer development, the disease is most often benign (2). When the heart is a secondary site of a cancer that began elsewhere, the prognosis does not tend to be very good. Most often, when cancer does spread from another site, it spreads to the heart from the lungs.

Primary Cardiac Lymphoma

Cases of primary cardiac lymphoma are very rare—just 90 cases have ever been reported in the medical literature (3)—but when they are diagnosed they tend to develop in the right atrium. From a diagnostic perspective, four out of five cases are diagnosed as diffuse large B-cell lymphoma (i.e. "primary cardiac B-cell lymphoma"). As a consequence, these cases tend to respond well to combination chemotherapy such as R-CHOP.

Because the heart is not part of the lymphatic system, primary cardiac lymphoma is classified as an extranodal lymphoma. More common sites of extranodal lymphomas include the breast, liver, skin, bone, eye and mouth (4).

Despite being a lymphoma, the symptoms that most often bring people with primary cardiac lymphoma aren't traditional lymphoma symptoms; rather, because the disease results in a tumor mass, the symptoms are directly related to faulty heart function. The three most common symptoms (or clinical manifestations) of primary cardiac lymphoma are (5):

  • Pericardial effusion. The heart is surrounded by a double-layered, sac-like structure called the pericardium. When too much fluid builds up here, it is called pericardial effusion and it prevents the heart from functioning properly.
  • Heart failure. Heart failure happens when the heart can't pump blood effectively because it is too weak or stiff to do so.
  • Atrioventricular block. This occurs when electrical signals sent through the atria don't reach the heart's ventricles.

Additional information for symptoms sourced from The Mayo Clinic.

Despite the extraordinary rarity of this lymphoma subtype, it serves as an example of the ability for lymphoma to develop virtually anywhere in the body.

Sources

1. CancerTreatment: Does Heart Cancer Exist?
2. PubMed: Cancer of the heart: epidemiology and management of primary tumors and metastases
3. PubMed: A rare case of primary cardiac B cell lymphoma
4. Lymphomation.org: extranodal lymphomas
5. PubMed: Primary cardiac lymphoma

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap